Published in Infect Immun on August 01, 1996
Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiol Mol Biol Rev (1998) 4.14
The cell wall-associated glyceraldehyde-3-phosphate dehydrogenase of Candida albicans is also a fibronectin and laminin binding protein. Infect Immun (1998) 1.42
Hemoglobin regulates expression of an activator of mating-type locus alpha genes in Candida albicans. Eukaryot Cell (2004) 0.99
Interactions of Candida albicans with host epithelial surfaces. J Oral Microbiol (2013) 0.90
Hemoglobin-induced binding of Candida albicans to the cell-binding domain of fibronectin is independent of the Arg-Gly-Asp sequence. Infect Immun (1998) 0.75
Iron and infection. Microbiol Rev (1978) 13.67
Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis (1972) 7.47
The significance of iron in infection. Rev Infect Dis (1982) 6.66
BACTERIOSTATIC AND LYTIC ACTIONS OF PENICILLIN ON SENSITIVE AND RESISTANT STAPHYLOCOCCI. J Clin Invest (1945) 4.96
Adherence and receptor relationships of Candida albicans. Microbiol Rev (1991) 4.24
The critical role of iron in host-bacterial interactions. J Clin Invest (1978) 3.87
Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med (1952) 3.81
Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media. Antimicrob Agents Chemother (1984) 3.74
Effects of pH on the activity of ketoconazole against Candida albicans. Antimicrob Agents Chemother (1983) 3.06
Penetration and damage of endothelial cells by Candida albicans. Infect Immun (1995) 2.67
Adhesive recognition sequences. J Biol Chem (1991) 2.38
A fibronectin receptor on Candida albicans mediates adherence of the fungus to extracellular matrix. J Infect Dis (1991) 1.78
Adhesins and ligands involved in the interaction of Candida spp. with epithelial and endothelial surfaces. Clin Microbiol Rev (1994) 1.76
Protein F: an adhesin of Streptococcus pyogenes binds fibronectin via two distinct domains. Mol Microbiol (1993) 1.65
Production of a hemolytic factor by Candida albicans. Infect Immun (1994) 1.43
The role of iron in nonspecific resistance to infection induced by endotoxin. J Immunol (1974) 1.40
Transferrin, iron, and dermatophytes. I. Serum dematophyte inhibitory component definitively identified as unsaturated transferrin. J Lab Clin Med (1975) 1.35
REVERSAL OF SERUM FUNGISTASIS BY ADDITION OF IRON. J Invest Dermatol (1964) 1.26
Elevated serum iron, low unbound transferrin and candidiasis in acute leukemia. Blood (1969) 1.25
Laminin binds specifically to sulfated glycolipids. Proc Natl Acad Sci U S A (1985) 1.25
The fibronectin adhesin of Candida albicans. Infect Immun (1994) 1.22
Adherence of Candida albicans to host cells. FEMS Microbiol Lett (1995) 1.18
Plasma and extracellular matrix proteins mediate in the fate of Candida albicans in the human host. Med Hypotheses (1994) 1.10
Multiple binding sites in fibronectin and the staphylococcal fibronectin receptor. Eur J Biochem (1992) 1.09
The relationship of transferrin and iron to serum inhibition of Candida albicans. J Invest Dermatol (1967) 1.06
The collagen binding domain of fibronectin contains a high affinity binding site for Candida albicans. J Biol Chem (1994) 1.05
Adherence of Candida albicans to human buccal epithelial cells: host-induced protein synthesis and signaling events. Infect Immun (1995) 1.02
Role of fibronectin in the pathogenesis of candidal infections. Rev Infect Dis (1988) 1.01
Gelatin fragments block adherence of Candida albicans to extracellular matrix proteins. Microbiology (1995) 0.94
Binding of plasma fibronectin to Candida albicans occurs through the cell binding domain. Microb Pathog (1994) 0.93
Candida albicans expresses a fibronectin receptor antigenically related to alpha 5 beta 1 integrin. Microbiology (1994) 0.93
Thrombospondin: biosynthesis, distribution, and changes associated with wound repair in corneal endothelium. Eur J Cell Biol (1990) 0.84
Biochemical studies on the interaction of fibronectin with Ig. J Immunol (1991) 0.83
The sequence of the human genome. Science (2001) 101.55
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.73
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids. Proc Natl Acad Sci U S A (1988) 3.83
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. Nature (1985) 3.53
Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005) 3.31
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother (1996) 3.03
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol (2008) 2.95
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75
Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis (1996) 2.72
Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother (2001) 2.68
Human mycoses: drugs and targets for emerging pathogens. Science (1994) 2.52
Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol (1997) 2.52
Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol (1995) 2.51
Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide (asialo GM1) and gangliotriaosylceramide (asialo GM2). Arch Biochem Biophys (1988) 2.49
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol (2005) 2.29
Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem (1995) 2.28
The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol (2005) 2.21
Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res (1994) 2.20
Reactivity of small thiolate anions and cysteine-25 in papain toward methyl methanethiosulfonate. Biochemistry (1986) 2.20
RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth Differ (2000) 2.13
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother (2001) 2.13
Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation (1999) 2.11
Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) (1986) 2.11
Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 2.11
Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis (2000) 2.09
Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol (1998) 2.09
Developments in hyalohyphomycosis and phaeohyphomycosis. J Med Vet Mycol (1994) 2.07
Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis (1994) 2.04
Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J Clin Microbiol (1987) 2.02
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (1998) 2.00
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol (2009) 1.99
Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis (1988) 1.95
Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 1.95
Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs (1992) 1.93
Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect (2001) 1.91
The platelet glycoprotein thrombospondin binds specifically to sulfated glycolipids. J Biol Chem (1985) 1.90
Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis (2001) 1.86
Neurotoxic effects of cisplatin therapy. Arch Neurol (1982) 1.83
Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res (1997) 1.81
Platelet thrombospondin mediates attachment and spreading of human melanoma cells. J Cell Biol (1987) 1.81
Adhesion of Mycoplasma pneumoniae to sulfated glycolipids and inhibition by dextran sulfate. J Biol Chem (1989) 1.76
Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol (2002) 1.72
Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis (1992) 1.71
Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis (1991) 1.70
Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice. Infect Immun (1989) 1.67
Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J (1996) 1.66
Distinction of deep versus superficial clinical and nonclinical isolates of Trichosporon beigelii by isoenzymes and restriction fragment length polymorphisms of rDNA generated by polymerase chain reaction. J Clin Microbiol (1991) 1.66
Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother (1994) 1.61
Rapid extraction of genomic DNA from medically important yeasts and filamentous fungi by high-speed cell disruption. J Clin Microbiol (1998) 1.60
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother (1999) 1.60
Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis (1997) 1.59
Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest (1998) 1.58
Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer (1994) 1.57
Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains. J Cell Biol (1987) 1.56
Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med (1995) 1.55
The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr (1991) 1.51
Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs (2001) 1.48
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother (1999) 1.48
Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Ann Neurol (1985) 1.45
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother (2001) 1.45
Infections due to Xylohypha bantiana (Cladosporium trichoides). Rev Infect Dis (1989) 1.45
Rem2, a new member of the Rem/Rad/Gem/Kir family of Ras-related GTPases. Biochem J (2000) 1.45
Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother (2001) 1.45
Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice. Antimicrob Agents Chemother (1986) 1.42
Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis (1992) 1.42
Histatin 3-mediated killing of Candida albicans: effect of extracellular salt concentration on binding and internalization. Antimicrob Agents Chemother (1999) 1.41
Late generalized tuberculosis: a clinical pathologic analysis and comparison of 100 cases in the preantibiotic and antibiotic eras. Medicine (Baltimore) (1980) 1.41
Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1. Mol Biol Cell (2000) 1.41
Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis (2008) 1.40
Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin Infect Dis (1992) 1.38
Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J Infect Dis (1994) 1.37
Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem (1993) 1.37
Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother (2000) 1.36
Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits. Antimicrob Agents Chemother (1990) 1.35
Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother (2001) 1.35
Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother (2001) 1.34
Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene (2013) 1.32
Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J Clin Microbiol (2000) 1.32
Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother (1989) 1.30
Validation of the Fournier's gangrene severity index in a large contemporary series. J Urol (2008) 1.30
Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by alpha3beta1 integrin and regulated by insulin-like growth factor-1 and CD98. J Biol Chem (1999) 1.29
Heparin-binding peptides from the type I repeats of thrombospondin. Structural requirements for heparin binding and promotion of melanoma cell adhesion and chemotaxis. J Biol Chem (1992) 1.27
Isolation and characterization of cell surface mutants of Candida albicans. Infect Immun (1990) 1.27
Laminin binds specifically to sulfated glycolipids. Proc Natl Acad Sci U S A (1985) 1.25
IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Immunol (1997) 1.24